I Want To...
Find a Doctor
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
Rakhi Prakash Naik, M.D.
Assistant Professor of Medicine
Expertise: Bleeding Disorders, Hematology, Hemoglobinopathies, Myelodysplastic/Myeloproliferative Neoplasms, Thromboembolic Disease
Johns Hopkins Bayview Medical Center
4940 Eastern Avenue
Baltimore, MD 21224 map
Dr. Naik is a board-certified hematologist who specializes in the treatment of adult patients with benign blood disorders and hematologic malignancies. Her primary focus is caring for patients with coagulation disorders such as abnormal bleeding and clotting, immune cytopenias such as ITP and TTP, and hemoglobinopathies. She sees patients at Johns Hopkins Bayview Medical Center.
- Assistant Professor of Medicine
Centers & Institutes
- MD, Weill Cornell Medical College (2006)
- Johns Hopkins University School of Medicine / Internal Medicine (2009)
- Johns Hopkins University School of Medicine / Oncology (2010)
- Johns Hopkins University School of Medicine / Oncology (2013)
- American Board of Internal Medicine / Hematology (2012)
- American Board of Internal Medicine / Internal Medicine (2010)
Research & Publications
Dr. Naik’s research focuses on the epidemiology of clinical complications of sickle cell trait, including chronic kidney disease and venous thromboembolism. Currently, very little is known about the clinical consequences of sickle cell trait. The goal of Dr. Naik's research is define the risk and modifying factors for disease related to sickle cell trait in order to inform genetic couseling, screening and treatment recommendations in individuals with trait.
Another main focus of Dr. Naik's research is the epidemiology and unique mechanisms of thrombosis in patients with hemoglobin disorders. Hypercoagulability in patients with hereditary hemoglobin disorders such as sickle cell disease results in severe complications such as venous thromboembolism and stroke. The primary aim of Dr. Naik’s research in this area is to characterize this thrombotic risk with the goal of identifying novel mechanisms of hypercoagulability and developing effective therapeutic strategies in patients with hemoglobinopathies.